Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with non-ionic radiocontrast media

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 865-869

  Fiaccadori, Enrico ^a   Maggiore, Umberto ^a   Rotelli, Carlo ^a   Giacosa, Roberto ^a   Lombard, Maria ^a   Sagripanti, Sibilla ^a   Buratti, Silvia ^b   Ardissino, Diego ^b   Cabassi, Aderville ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b Azienda Ospedaliera Universitaria   (Italy)

Author keywords

Nephrotoxicity; Oxidative stress; Peroxynitrite; Radiocontrast media

Indexed keywords

3 NITROTYROSINE; ACETYLCYSTEINE; BIOLOGICAL MARKER; CREATININE; IOPROMIDE; NITRIC OXIDE; NITROGEN; NONIONIC CONTRAST MEDIUM; OXYGEN; PEROXYNITRITE; RADICAL; SUPEROXIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CHEMICAL REACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CREATININE URINE LEVEL; FEMALE; HEART CATHETERIZATION; HUMAN; MALE; NEPHROTOXICITY; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TYROSINE;

EID: 1842418627     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh039     Document Type: Article

References (20)

1. Murphy SW, Barret BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 1: 177-182
2. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184
3. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-358
4. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383-1388
5. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. J Am Med Assoc 2003; 289: 553-558
6. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol 2003; 41: 2114-2118
7. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303
8. Allaqaband S, Tumuluri R, Malik AM et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57: 279-283
9. Durham JD, Caputo C, Dokko J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-2207
10. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003; 58: 336-341
11. Noiri E, Nakao A, Uchida K et al. Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol 2001; 281: F948-F957
12. Cabassi A, Bouchard JF, Dumont EC et al. Effect of antioxidant treatments on nitrate tolerance development in normotensive and hypertensive rats. J Hypertens 2000; 18: 187-196
13. ter Steege JC, Koster-Kamphuis L, van Straaten EA et al. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radical Biol Med 1998; 25: 953-963
14. Mora Mangano C, Diamondstone LS, Ramsay JG et al. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 1998; 128: 194-203
15. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: Role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003; 44: 3135-3143
16. Goldfarb RD, Marton A, Szabo E et al. Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 2002; 30: 974-980
17. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143: 894-903
18. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: A role for medullary hypoxia. Invest Radiol 1999; 34: 685-691
19. Katholi RE, Woods WT Jr, Taylor GJ et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64-71
20. Freeman RV, O'Donnell M, Share D et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068-1073